ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OCX Oncocyte Corporation

2.72
0.01 (0.37%)
Apr 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 110,351
Bid Price 2.66
Ask Price 2.72
News -
Day High 2.6381

Low
2.08

52 Week Range

High
6.80

Day Low 2.5101
Company Name Stock Ticker Symbol Market Type
Oncocyte Corporation OCX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.37% 2.72 19:57:15
Open Price Low Price High Price Close Price Prev Close
2.59 2.5101 2.6381 2.53 2.71
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
800 110,351 $ 2.54 $ 280,585 - 2.08 - 6.80
Last Trade Time Type Quantity Stock Price Currency
19:57:15 formt 500 $ 2.72 USD

Oncocyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
21.06M 8.26M - 31.98M -73.42M -8.89 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Oncocyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No OCX Message Board. Create One! See More Posts on OCX Message Board See More Message Board Posts

Historical OCX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.913.302.512.74482,590-0.19-6.53%
1 Month2.903.302.512.75132,136-0.18-6.21%
3 Months3.303.442.512.7849,869-0.58-17.58%
6 Months3.104.342.082.8633,663-0.38-12.26%
1 Year6.006.802.084.2692,142-3.28-54.67%
3 Years103.20125.002.0839.60349,089-100.48-97.36%
5 Years69.80125.002.0844.65368,719-67.08-96.10%

Oncocyte Description

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Your Recent History

Delayed Upgrade Clock